Cystic Fibrosis Microbiome
Brief description of study
Among lung transplant recipients who survive to 5 years, half suffer from chronic lung allograft dysfunction (CLAD). This study will evaluate how changes in the lung microbiome may cause CLAD in Cystic Fibrosis patients who have been transplanted.
This is a case-control study of Cystic Fibrosis lung transplant recipients to define the lower respiratory tract microbiome at the time of incident CLAD and determine the relationship between allograft microbiome, host response, and CLAD.
Patients with clinical CLAD who are scheduled to undergo clinical bronchoscopy will be recruited for this study alongside matched control subjects that will undergo research bronchoscopy for sample collection.
Subjects will be recruited from
established patients within the University of Pennsylvania, Johns
Hopkins University, and University of Pittsburgh Lung Transplant
Programs.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
cystic fibrosis
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 834250
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
